COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IKK-B GENE

• Main Authors: FOUGEROLLES, ANTONIN DE, HARDAKER, ELIZABETH LOUISE, CATLEY, MATTHEW COPELAND, SPRAGUE, ANDREW, BIRRELL, MARK ANDREW, BELVISI, MARIA GABRIELA, HARBORTH, JENS
• Format: Patent
• Language: English; French
• Published: 29.11.2007
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; VINEGAR; WINE

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the IKK-B gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the IKK-B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression or activation of the IKK-B gene using the pharmaceutical composition; and methods for inhibiting the expression of the IKK-B gene in a cell. L'invention porte sur de l'ARN double brin (dsRNA) inhibant l'expression du gène IKK-B et comprenant un brin antisens dont la séquence nucléotidique, d'une longueur de moins de 30 nucléotides et normalement de 19 à 25 nucléotides, est sensiblement complémentaire d'au moins une partie de celle du gène IKK-B. L'invention porte également un préparation pharmaceutique contenant ledit ARN asssocié à un vecteur pharmacocompatible, sur des méthodes de traitement de maladies causées par l'expression ou l'activation du gène IKK-B utilisant ladite préparation pharmaceutique, et sur des méthodes d'inhibition de l'expression du gène IKK-B dans une cellule.